SG Americas Securities LLC Grows Stock Holdings in Kenvue Inc. (NYSE:KVUE)

SG Americas Securities LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 97.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 562,678 shares of the company’s stock after buying an additional 277,697 shares during the period. SG Americas Securities LLC’s holdings in Kenvue were worth $13,015,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC raised its position in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after acquiring an additional 530 shares during the last quarter. Mather Group LLC. acquired a new position in Kenvue during the first quarter worth about $28,000. Riverview Trust Co acquired a new position in Kenvue during the first quarter worth about $33,000. MV Capital Management Inc. raised its position in Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in Kenvue during the first quarter worth about $33,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.5 %

KVUE stock traded down $0.11 on Friday, hitting $22.16. 8,451,647 shares of the company were exchanged, compared to its average volume of 18,410,244. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $23.55. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The business’s fifty day moving average is $21.84 and its two-hundred day moving average is $20.16. The stock has a market capitalization of $42.43 billion, a price-to-earnings ratio of 28.41, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. During the same quarter in the prior year, the business posted $0.32 earnings per share. Kenvue’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were paid a dividend of $0.205 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 annualized dividend and a yield of 3.70%. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s payout ratio is currently 105.13%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KVUE. Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective for the company. UBS Group boosted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Citigroup cut their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $22.10.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.